natgillin/translations-raw huggingface dataset:
The European Medicines Agency has waived the obligation to submit the results of studies with Suliqua in all subsets of the paediatric population for treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Suliqua za vse podskupine pediatrične populacije za zdravljenje sladkorne bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
- lixisenatide and/or insulin in combination with a sulfonylurea may result in an increased risk of hypoglycaemia.
- liksisenatid in/ali insulin lahko v kombinaciji s sulfonilsečnino povečata tveganje za hipoglikemijo.
Suliqua is used to treat adults with type 2 diabetes, to help control blood sugar levels when they are too high.
Zdravilo Suliqua se uporablja za zdravljenje odraslih s sladkorno boleznijo tipa 2, da pomaga obvladati koncentracijo krvnega sladkorja, kadar je previsoka.
• This will make sure you get your full dose.
• Tako boste zagotovili, da boste dobili celoten odmerek.
• Your pen contains a total of 300 dose steps.
• Peresnik vsebuje 300 odmernih korakov.
• Lithium salts, for mental health problems.
• Litijeve soli, za težave z duševnim zdravjem.
Other medicines and Suliqua
Druga zdravila in zdravilo Suliqua
• you have a severe stomach or gut problem such as a disease of the muscles of the stomach called “gastroparesis” which results in delayed stomach emptying.
• če imate hude težave z želodcem ali črevesjem, npr. bolezen želodčnih mišic, imenovano "gastropareza", ki upočasni praznjenje želodca.
* Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of ≤3.9 mmol/L.
* Dokumentirana simptomatska hipoglikemija je bila pojav značilnih simptomov hipoglikemije, ki jih je spremljala izmerjena koncentracija glukoze v plazmi ≤ 3,9 mmol/l.
• you have diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to use glucose because there is not enough insulin) since this medicine will not be right for you.
• če imate diabetično ketoacidozo (to je zaplet sladkorne bolezni, ki se pojavi, če telo ne more uporabljati glukoze, ker ni dovolj insulina), kajti v takšnem primeru to zdravilo ni primerno za vas.
The cartridge should be inspected before use.
Vložek je treba pred uporabo pregledati.
In embryo-foetal development studies, malformations, growth retardation, ossification retardation and skeletal effects were observed in rats at all doses (5-fold exposure ratio compared to human exposure) and in rabbits at high doses (32-fold exposure ratio compared to human exposure) of lixisenatide.
V študijah embrio-fetalnega razvoja so malformacije, upočasnitev rasti, zapoznelo osifikacijo in skeletne učinke pri podganah opažali ob vseh odmerkih (5-kratno razmerje izpostavljenosti v primerjavi z izpostavljenostjo pri človeku) ter pri kuncih ob velikih odmerkih (32-kratno razmerje izpostavljenosti v primerjavi z izpostavljenostjo pri človeku) liksisenatida.
• For information on the treatment of hyperglycaemia, see the box at the end of this leaflet.
• Za informacije o zdravljenju hiperglikemije glejte okvir na koncu tega navodila.
The safety and effectiveness of Suliqua on glycaemic control were evaluated in two randomised clinical studies in patients with type 2 diabetes mellitus:
Varnost in učinkovitost zdravila Suliqua za urejanje glikemije so ocenili v dveh randomiziranih kliničnih študijah pri bolnikih s sladkorno boleznijo tipa 2:
To avoid mistakes, always check the medicine pack and label on the pen before each injection to make sure you have the correct pen, especially if you inject more than one medicine.
Da boste preprečili napake, vedno pred vsakim injiciranjem preverite pakiranje zdravila in nalepko na peresniku ter se tako prepričajte, da imate pravi peresnik, še zlasti če si injicirate več kot eno zdravilo.
• Ensure that your patients and their caretakers are adequately informed on how to use insulin glargine/lixisenatide.
• Poskrbite, da bodo bolniki in njihovi negovalci ustrezno seznanjeni s tem, kako uporabljati insulin glargin/liksisenatid.
• Always check the label of the pen before use to make sure you have the correct pen.
• Pred uporabo vedno preverite nalepko peresnika, da se prepričate da imate ustrezen peresnik.
In a 28-day placebo-controlled study in patients with type 2 diabetes 5 to 20 mcg lixisenatide resulted in a statistically significant decreases in postprandial blood glucose after breakfast, lunch and dinner.
V 28-dnevni s placebom kontrolirani študiji pri bolnikih s sladkorno boleznijo tipa 2 je liksisenatid v odmerku od 5 do 20 mcg statistično značilno znižal postprandialno glukozo v krvi po zajtrku, kosilu in večerji.
In 2-year subcutaneous carcinogenicity studies, non-lethal C-cell thyroid tumors were seen in rats and mice and are considered to be caused by a non-genotoxic GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive.
V 2-letnih študijah kancerogenosti med subkutano uporabo so pri podganah in miših ugotovili neusodne ščitnične tumorje celic C; za te tumorje velja, da nastanejo zaradi negenotoksičnega mehanizma preko receptorjev GLP-1, za katerega so glodalci posebej občutljivi.
Your concentration may be affected.
Prizadeta je lahko vaša zbranost.
Change the injection site with each injection to help prevent these changes.
Mesto injiciranja zamenjajte pri vsakem injiciranju, da boste preprečili takšne spremembe.
The starting dose of Suliqua isbased on previous anti-diabetic treatment, and in order not to exceed the recommended lixisenatide starting dose of 10 mcg:
Začetni odmerek zdravila Suliqua temelji na predhodnem antidiabetičnem zdravljenju; da ne bi prekoračili priporočenega začetnega odmerka 10 mcg liksisenatida, je treba upoštevati naslednje:
Your doctor may tell you to use a different dose of Suliqua compared to your previous insulin dose.
Zdravnik vam lahko naroči, da uporabljajte drugačen odmerek zdravila Suliqua, kot je bil odmerek prejšnjega insulina.
• Only use your pen for up to 28 days after its first use.
• Peresnik uporabljajte največ 28 dni po prvi uporabi.
Examples include:
Med možnimi vzroki so:
However, the patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
Vendar pa se bolnikova zmožnost zbranosti in reagiranja lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi okvare vida.
• Change the place within the area you inject each day.
• Vsak dan zamenjajte mesto na predelu, kamor injicirate zdravilo.
• Only use needles that are compatible with Suliqua pen (see “Instructions for Use”).
• Uporabljajte le igle, ki so združljive s peresnikom Suliqua (glejte "Navodila za uporabo").
Following a standardised labelled test meal, in the study referred to above, it was confirmed that lixisenatide slows gastric emptying, thereby reducing the rate of postprandial glucose absorption.
Po standardiziranem označenem testnem obroku so v zgoraj omenjeni študiji potrdili, da liksisenatid upočasni praznjenje želodca in tako zmanjša hitrost absorpcije glukoze po obroku.
Excipient(s) with known effects: Each ml contains 2.7 milligrams of metacresol.
Pomožne snovi z znanim učinkom: En ml vsebuje 2,7 miligrama metakrezola.
• Do not press at an angle.
• Ne pritiskajte pod kotom.
• You are taking or have taken certain other medicines (see section 2, "Other medicines and
• Jemljete ali ste jemali določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo
The incidence of the primary endpoint was similar in the lixisenatide (13.4%) and placebo (13.2%) groups: the hazard ratio (HR) for lixisenatide versus placebo was 1.017, with an associated 2-sided 95% confidence interval (CI) of 0.886 to 1.168.
Incidenca primarnega opazovanega dogodka je bila v skupini z liksisenatidom (13,4 %) in skupini s placebom (13,2 %) podobna: razmerje ogroženosti (ROg) za liksisenatid v primerjavi s placebom je bilo 1,017 in 2-stranski 95 % interval zaupanja (IZ) za to vrednost je bil od 0,886 do 1,168.
After holding and slowly counting to 10, release the injection button.
Potem, ko ste gumb držali in počasi prešteli do 10, gumb za injiciranje spustite.
In 2-year subcutaneous carcinogenicity study in mice, 3 cases of adenocarcinoma in the endometrium were seen in the mid dose group with a statistically significant increase, corresponding to an exposure ratio of 97-fold.
V 2-letni študiji kancerogenosti med subkutano uporabo pri miših so v skupini s srednjo ravnjo odmerka ugotovili 3 primere adenokarcinoma v endometriju s statistično značilnim povečanjem ob 97-kratnem razmerju izpostavljenosti.
• Skin and allergic reactions at the injection site: The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation.
• Kožne in alergijske reakcije na mestu injiciranja: Med znaki so lahko pordelost, nenavadno močna bolečina pri injiciranju, srbenje, koprivnica, oteklost ali vnetje.
• Lixisenatide: a “GLP-1 analogue” that helps the body produce its own additional insulin in response to increases in blood sugar, and slows the absorption of sugar from foods.
• liksisenatid: "analog GLP-1", ki telesu pomaga izdelovati lasten dodatni insulin v odziv na zvišanje krvnega sladkorja in upočasni absorpcijo sladkorja iz hrane.
This may mean your Suliqua dose has to change.
To lahko pomeni, da je treba odmerek zdravila Suliqua spremeniti.
In a pre-specified analysis of this primary endpoint, the differences observed were consistent with regard to baseline HbA1c (<8% or ≥8%) or baseline OAD use (metformin alone or metformin plus second OAD).
V vnaprej opredeljeni analizi tega primarnega opazovanega dogodka so bile opažene razlike dosledne glede na izhodiščni HbA1c (< 8 % ali ≥ 8 %) ali izhodiščno uporabo POAD (samo metformin ali metformin skupaj s še enim POAD).
• Foods containing sugar, such as dextrose tablets or a sugary drink (at least 20 grams).
• Hrano, ki vsebuje sladkor, na primer tablete glukoze ali sladko pijačo (vsaj 20 gramov sladkorja).
The ELIXA study was a randomised, double-blind, placebo-controlled, multinational study that evaluated cardiovascular (CV) outcomes during treatment with lixisenatide in patients (n=6068) with type 2 diabetes mellitus after a recent Acute Coronary Syndrome.
Študije ELIXA je bila randomizirana, dvojno slepa, s placebom kontrolirana multinacionalna študija, ki je ocenjevala srčno-žilne (SŽ) izide med zdravljenjem z liksisenatidom pri bolnikih (n = 6068) s sladkorno boleznijo tipa 2 po nedavnem akutnem koronarnem sindromu.
You might then need to eat something (such as bread or pasta) that will raise your blood sugar over a longer time, especially if your next meal is not due.
Potem boste morda morali zaužiti kaj, kar krvni sladkor zviša za dalj časa (na primer kruh ali testenine), zlasti če še ni čas za vaš naslednji obrok.
You can select your dose in steps of 1 dose step.
Odmerek lahko nastavite v korakih po 1 odmerni korak.
More severe episodes of hypoglycaemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere hipoglikemij s komo, konvulzijami ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano ali s koncentrirano glukozo intravensko.
Shelf-life after first use of the pen: 28 days
Rok uporabnosti po prvi uporabi injekcijskega peresnika: 28 dni
Hypoglycaemia is also more likely to happen if:
Prav tako je hipoglikemija bolj verjetna:
The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from beta cells and suppresses glucagon from alpha cells in the pancreas.
Receptor GLP-1 je cilj naravnega GLP-1; to je endogeni inkretinski hormon, ki poveča od glukoze odvisno izločanje insulina iz pankreatičnih celic beta in zavre izločanje glukagona iz pankreatičnih celic alfa.
The primary composite efficacy endpoint was the time to the first occurrence of any of the following events: Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for unstable angina.
Primarni sestavljeni opazovani dogodek učinkovitosti je bil čas do prvega pojava katerega koli od naslednjih dogodkov: srčno-žilne smrti, miokardnega infarkta brez smrtnega izida, možganske kapi brez smrtnega izida ali sprejema v bolnišnico zaradi nestabilne angine pektoris.
Your thumb could block the dose selector from turning.
S palcem namreč lahko onemogočite obračanje izbirnika odmerka.
• You are taking or have stopped taking certain other medicines (see section 2, "Other medicines and Suliqua").
• Jemljete ali ste nehali jemati določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo Suliqua").
You should test your blood sugar straight away after taking glucose to check that you really have hypoglycaemia.
Krvni sladkor si morate izmeriti takoj po zaužitju glukoze; tako boste preverili, da res imate hipoglikemijo.
Some (1.7%) patients taking insulin containing therapy, including Suliqua have experienced erythema, local edema, and pruritus at the site of injection.
Pri nekaterih (1,7 %) bolnikih, ki so prejemali zdravljenje, ki vsebuje insulin, vključno z zdravilom Suliqua, so se pojavili pordelost, lokalna oteklina in srbenje na mestu injiciranja.
• Patient Guide.
• Vodnik za bolnike.
Do not return the pen to a refrigerator and do not freeze.
Peresnika ne dajte nazaj v hladilnik in ga ne zamrznite.
Based on your lifestyle, your blood sugar tests and your previous insulin use, your doctor will tell you:
Zdravnik vam bo glede na vaš slog življenja, izvide meritev krvnega sladkorja in prejšnjo uporabo insulina povedal:
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
Če imate previsok krvni sladkor (hiperglikemijo), si morda niste injicirali dovolj insulina.
D. Pull off the inner needle cap and throw away.
D. Snemite notranji pokrovček igle in ga zavrzite.
The medicine may not work very well.
Delovanje zdravila se lahko poslabša.
The median duration of study follow-up was 25.8 and 25.7 months in the lixisenatide group and the placebo group, respectively.
Mediano spremljanje v študiji je trajalo v skupini z liksisenatidom 25,8 mesece in v skupini s placebom 25,7 meseca.
Check your blood sugar and eat more food to prevent your blood sugar getting too low (hypoglycaemia).
Merite si krvni sladkor in jejte več hrane, da boste preprečili preveliko znižanje krvnega sladkorja (hipoglikemijo).
To avoid dosing errors and potential overdose, neither the patients nor healthcare professionals should ever use a syringe to draw the medicinal product from the cartridge in the pre-filled pen into a syringe.
Da ne bi prišlo do napak pri odmerjanju in možnega prevelikega odmerjanja, ne smejo bolniki ali zdravstveno osebje nikdar uporabiti brizge, da bi zdravilo iz vložka napolnjenega injekcijskega peresnika potegnili v brizgo.
• Fibrates, for lowering high levels of blood fats.
• Fibrate, za znižanje visoke koncentracije maščob v krvi.
• When medicine comes out of the needle tip, your pen is working correctly, the dose selector will be reset to “0”.
• Če iz konice igle priteče zdravilo, peresnik deluje pravilno; izbirnik odmerka se bo pomaknil nazaj na "0".
Lixisenatide is a glucagon-like peptide (GLP1) receptor agonist.
Liksisenatid je agonist receptorjev glukagonu podobnega peptida (GLP1).
Sanofi-Aventis Deutschland GmbH Industriepark Höchst - 65926 Frankfurt am Main Germany
Sanofi-Aventis Deutschland GmbH Industriepark Höchst - 65926 Frankfurt am Main Nemčija
• You inject too much Suliqua.
• Injicirali ste si preveč zdravila Suliqua.
Ask your pharmacist how to throw away medicines you no longer used.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom .
After multiple-dose administration in patients with type2 diabetes, mean terminal half-life was approximately 3 hours and the mean apparent clearance (CL/F) about 35 L/h.
Po uporabi več odmerkov pri sladkornih bolnikih tipa 2 je bil povprečni terminalni razpolovni čas približno 3 ure in povprečni navidezni očistek (CL/F) približno 35 l/uro.
C. Throw away the used needle in a puncture resistant container (see “Throwing your pen away” at the end of this Instructions for Use).
C. Uporabljeno iglo zavrzite v vsebnik, odporen proti prebadanju (glejte "Kako zavreči peresnik" na koncu teh navodil).
• Pentamidine, for some parasite infections.
• Pentamidin, za nekatere okužbe z zajedavci.
Use Suliqua once a day, within 1 hour before a meal.
Zdravilo Suliqua uporabljajte enkrat na dan, 1 uro pred jedjo.
A. Select 2 dose steps by turning the dose selector until the dose pointer is at the 2 mark.
A. Izberite 2 odmerna koraka tako, da zavrtite izbirnik odmerka, dokler kazalnik odmerka ne kaže oznake 2.
Documented symptomatic or severe hypoglycaemic adverse reactions
Dokumentirane simptomatske ali hude hipoglikemije
In controlled clinical trials in adults with insulin glargine (100 units/ml), subgroup analyses based on age, race, and gender did not show differences in safety and efficacy.
V kontroliranih kliničnih preskušanjih insulina glargin (100 enot/ml) analize podskupin glede na starost, raso in spol niso pokazale razlik v varnosti in učinkovitosti.
If a patient wishes to become pregnant, or pregnancy occurs, treatment with Suliqua should be discontinued.
Če bolnica želi zanositi ali če zanosi, je treba zdravljenje z zdravilom Suliqua prekiniti.
Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Insulin zavira lipolizo in proteolizo in pospešuje sintezo beljakovin.
Following administration of a single dose of paracetamol 1000 mg, paracetamol AUC and t1/2 were unchanged whatever the timing of its administration (before or after the lixisenatide injection).
Po uporabi enkratnega odmerka 1000 mg paracetamola se AUC in t1/2 paracetamola ne glede na čas njegove uporabe (pred injiciranjem liksisenatida ali po njem) nista spremenila.
With Suliqua, it may take longer to recover from low blood sugar because it contains a long-acting insulin (insulin glargine).
Med zdravljenjem z zdravilom Suliqua lahko okrevanje po nizkem krvnem sladkorju traja dalj časa, ker to zdravilo vsebuje dolgodelujoč insulin (insulin glargin).
In patients treated with Suliqua, the incidence of related nausea, diarrhoea and vomiting was 8.4%, 2.2% and 2.2%, respectively.
Pri bolnikih, zdravljenih z zdravilom Suliqua, je bila incidenca s tem povezane navzee 8,4 %, driske 2,2 % in bruhanja 2,2 %.
These other medicines may include oral anti-diabetics (such as metformin, sulfonylurea medicines) or insulin.
Med temi drugimi zdravili so lahko peroralni antidiabetiki (na primer metformin ali sulfonilsečnine) ali insulin.
• Keep new pens in the refrigerator between 2°C to 8°C.
• Nove peresnike shranjujte v hladilniku na temperaturi od 2 do 8 °C.
• A safety test must be performed before each injection.
• Pred vsakim injiciranjem morate opraviti varnostni preizkus.
• Throw away the used needle in a sharps container, or as told by your pharmacist or local authority.
• Uporabljene igle zavrzite v vsebnik za ostre odpadke, ali kot vam naroči farmacevt ali pristojni lokalni organ.
Gastrointestinal adverse reactions (nausea, vomiting and diarrhoea) were frequently reported adverse reactions during the treatment period.
Neželeni učinki na prebavilih (navzea, bruhanje ali driska) so bili med obdobjem zdravljenja pogosto zabeleženi neželeni učinki.
The incidence of MACE was similar between LANTUS and standard care in ORIGIN [Hazard Ratio (95% CI) for MACE; 1.02 (0.94, 1.11)].
Incidenca MACE je bila v študiji ORIGIN v skupini z zdravilom LANTUS podobna kot v skupini z običajnim zdravljenjem [razmerje ogroženosti (95 % IZ) za MACE; 1,02 (0,94, 1,11)].
• Diazoxide, for high blood pressure.
• Diazoksid, za visok krvni tlak.
In the event of blocked needles, patients must follow the instructions described in the Instructions for Use accompanying the package leaflet (see section 6.6).
Če je igla zamašena, mora bolnik slediti navodilom, opisanim v navodilih za uporabo, priloženih navodilu za uporabo zdravila (glejte poglavje 6.6).
• you have type 1 diabetes, as Suliqua is used for type 2 diabetes and this medicine will not be right for you.
• če imate sladkorno bolezen tipa 1, kajti zdravilo Suliqua se uporablja za zdravljenje sladkorne bolezni tipa 2 in tako ni primerno za vas.
There are no adequate data from the use of lixisenatide in pregnant women.
O uporabi liksisenatida pri nosečnicah ni dovolj podatkov.
The reduction in Cmax is of limited clinical relevance and no dose adjustment for oral contraceptives is required.
Znižanje Cmax je klinično malo pomembno in odmerka kontraceptivov ni treba prilagoditi.
Type I colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with inserted laminated sealing disks (bromobutyl rubber on the medicinal product side and polyisoprene on the outside) containing 3 ml of solution.
Vložek iz brezbarvnega stekla tipa I s črnim batom (iz brombutilne gume) in obrobljeno zaporko (aluminij) z vstavljenimi laminiranimi zapornimi diski (brombutilna guma na strani zdravila in poliizopren na zunanji strani), ki vsebujejo 3 ml raztopine.
Exposure to insulin glargine following administration of the insulin glargine/lixisenatide combination was 86-88 % compared to administration of separate simultaneous injections of insulin glargine and lixisenatide.
Izpostavljenost insulinu glargin po uporabi kombinacije insulin glargin/liksisenatid je bila od 86 do 88 % v primerjavi s sočasno uporabo ločenih injekcij insulina glargin in liksisenatida.
For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before or 4 hours after lixisenatide injection.
Za peroralna zdravila, katerih učinkovitost je zlasti odvisna od mejnih koncentracij, kot so antibiotiki, moramo bolnikom svetovati, naj takšna zdravila vzamejo vsaj 1 uro pred injiciranjem liksisenatida ali 4 ure po injiciranju.
Other signs include: headaches, feeling very hungry, feeling sick (nausea) or being sick (vomiting), feeling tired, sleepy, restless, sleeping problems, aggressive behaviour, difficulty concentrating, slow reactions, depression, feeling confused, difficulty speaking (sometimes total loss of speech), changes in your sight, trembling, being unable to move (paralysis), tingling in the hands or arms, feeling numb and tingling often around the mouth, feeling dizzy, loss of self-control, being unable to look after yourself, fits, passing out.
Med drugimi znaki so glavobol, huda lakota, slabost v želodcu (siljenje na bruhanje) ali bruhanje, utrujenost, zaspanost, nemir, težave s spanjem, agresivno vedenje, težave z zbranostjo, počasne reakcije, potrtost, občutek zmedenosti, težave z govorom (včasih popolna izguba govora), spremembe vida, tresenje, nezmožnost gibanja (paraliza), mravljinčenje v rokah ali dlaneh, omrtvičenost in mravljinčenje, pogosto okrog ust, omotičnost, izguba samonadzora, nezmožnost poskrbeti zase, napadi krčev, nezavest.
• Tell patients to closely monitor their blood sugar levels when starting insulin glargine/lixisenatide which contains insulin glargine and a non-insulin active substance (lixisenatide).
• Bolnikom naročite, naj natančno spremljajo koncentracijo krvnega sladkorja, ko začnejo zdravljenje z insulinom glarginom/liksisenatidom, ki vsebuje insulin glargin in neinsulinsko učinkovino (liksisenatid).
Suliqua has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and therefore, the use of Suliqua is not recommended in these patients.
Zdravilo Suliqua ni raziskano pri bolnikih s hudo boleznijo prebavil, vključno s hudo gastroparezo, zato ga pri takšnih bolnikih ni priporočljivo uporabljati.
It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
Uporabite ga le, če je raztopina v njem bistra, brezbarvna, ne vsebuje vidnih trdnih delcev in je vodi podobne gostote.